Trial
NCT02658877
Sputum-derived Cellular Targets After Xolair (Omalizumab)
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
—
Condition
Asthma
Intervention
Omalizumab
Why stopped
Difficulty recruiting subjects
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-30